Skip to content

Study · In vitro (cells) · 1996

4 results

Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells.

Moshier JA, Mutchnick MG, Dosescu J, Holtz TK, Akkary S, Mahakala K, Merline JR, Naylor PH

Journal of hepatology1 Dec 1996Cited by 10 (Europe PMC)

PMID9007707 (opens in a new tab)DOI10.1016/s0168-8278(96)80283-2 (opens in a new tab)PepBankPUB-09007707
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In HBV-transfected HepG2-Nu2 cells, thymosin alpha‑1 inhibited anchorage-independent growth by 40% compared with untreated controls.

    In plain wordsIn lab tests on liver cancer cells carrying hepatitis B DNA, thymosin alpha‑1 slowed colony growth by 40% compared with untreated cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAnchorage-independent growth of HepG2-Nu2 cells
    Study

    n: not reported in source

    HepG2-Nu2 (HBV-transfected HepG2) hepatoblastoma cells
    Comparator
    Untreated controls
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    growth inhibition
    40%
    HepG2-Nu2 cells

    Source sentences

    Summary
    thymosin-alpha 1 inhibited the anchorage-independent growth of the HepG2-Nu2 cells by 40% compared with untreated controls
    1 context sentence
    Summary · context
    In this study, hepatitis B transfected HepG2 hepatoblastoma cells (HepG2-Nu2), derived from 2.2.15 cells, were used as an in vitro model to determine the efficacy of thymosin-alpha 1 and interferon-alpha, individually and combined, as proliferation inhibitors of HBV-infected cells.
  2. 02LabIn vitro (cells)Activity measurement

    In parental HepG2 and SV40-transfected HepG2P9T2 cells, thymosin alpha‑1 did not inhibit clonal growth.

    In plain wordsIn lab tests on two other liver cancer cell lines without hepatitis B DNA, thymosin alpha‑1 did not slow colony growth.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeAnchorage-independent growth of parental HepG2 and HepG2P9T2 cells
    Study

    n: not reported in source

    parental HepG2 and SV40-transfected HepG2P9T2 cells
    Comparator
    Untreated controls
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but did not inhibit parental HepG2 or HepG2P9T2 clonal growth.
    2 context sentences
    Summary · context
    For comparison, parental HepG2 cells and an SV40-transfected HepG2 cell line (HepG2P9T2) were also evaluated.
    Summary · context
    In this study, hepatitis B transfected HepG2 hepatoblastoma cells (HepG2-Nu2), derived from 2.2.15 cells, were used as an in vitro model to determine the efficacy of thymosin-alpha 1 and interferon-alpha, individually and combined, as proliferation inhibitors of HBV-infected cells.
  3. 03LabIn vitro (cells)Activity measurement

    In HepG2-Nu2 cells, the growth inhibition by thymosin alpha‑1 was dose dependent over three log units of concentration.

    In plain wordsIn lab tests on liver cancer cells carrying hepatitis B DNA, higher doses of thymosin alpha‑1 slowed growth more over a wide range.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDose dependence of growth inhibition in HepG2-Nu2 cells
    Study

    n: not reported in source

    HepG2-Nu2 (HBV-transfected HepG2) hepatoblastoma cells
    Comparator
    Untreated controls
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The response was dose dependent over concentrations spanning three log units.
    1 context sentence
    Summary · context
    In this study, hepatitis B transfected HepG2 hepatoblastoma cells (HepG2-Nu2), derived from 2.2.15 cells, were used as an in vitro model to determine the efficacy of thymosin-alpha 1 and interferon-alpha, individually and combined, as proliferation inhibitors of HBV-infected cells.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In HepG2-Nu2 cells, thymosin alpha‑1 combined with interferon-alpha inhibited clonal growth more effectively than either treatment alone, up to 51%.

    In plain wordsIn lab tests on liver cancer cells carrying hepatitis B DNA, thymosin alpha‑1 plus interferon-alpha slowed growth more than either alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseGrowth inhibition by thymosin-alpha 1 plus interferon-alpha
    Study

    n: not reported in source

    HepG2-Nu2 (HBV-transfected HepG2) hepatoblastoma cells
    Comparator
    Thymosin-alpha 1 alone, interferon-alpha alone
    Outcome group
    Tumor growth · Cancer

    Measurements

    maximum inhibition
    51%
    HepG2-Nu2 cells, combination

    Source sentences

    Summary
    The combination of thymosin-alpha 1 and interferon-alpha consistently inhibited HepG2-Nu2 clonal growth more effectively than either treatment alone, reaching maximum inhibition levels of 51%.
    1 context sentence
    Summary · context
    In this study, hepatitis B transfected HepG2 hepatoblastoma cells (HepG2-Nu2), derived from 2.2.15 cells, were used as an in vitro model to determine the efficacy of thymosin-alpha 1 and interferon-alpha, individually and combined, as proliferation inhibitors of HBV-infected cells.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.